{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-299290","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2026-07-09T13:31:32+00:00","discovered_at":"2026-07-09T13:32:00.245850+00:00","generated_at":"2026-07-09T13:32:05.772398+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"FibroBiologics appoints former NASA astronaut Kathleen Rubins to board; director Matt Link resigns","bullets":["Matt Link resigned from the board effective July 2, 2026.","Kathleen Rubins appointed as Class III director effective July 8, 2026, term until 2029 annual meeting.","Rubins also appointed to Audit, Compensation, and Governance Committees.","Rubins is a retired NASA astronaut, microbiologist, and founding director of Trivedi Institute at University of Pittsburgh.","She previously served on FibroBiologics' Scientific Advisory Board since 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-299290","json":"https://secwatch.observer/filing/0001193125-26-299290.json","markdown":"https://secwatch.observer/filing/0001193125-26-299290.md","text":"https://secwatch.observer/filing/0001193125-26-299290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/fblg-20260702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T13:32:05.772398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041efa33c4","claim":"Matt Link resigned as Director at FibroBiologics, Inc..","evidence_excerpt":"On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1962f21344","claim":"Kathleen Rubins was appointed as Class III Director at FibroBiologics, Inc..","evidence_excerpt":"On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}